Cookson Peirce & Co. Inc. Purchases Shares of 6,213 Halozyme Therapeutics, Inc. $HALO

Cookson Peirce & Co. Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 6,213 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Royal London Asset Management Ltd. grew its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after purchasing an additional 200,262 shares in the last quarter. Hsbc Holdings PLC raised its stake in Halozyme Therapeutics by 452.1% in the second quarter. Hsbc Holdings PLC now owns 158,889 shares of the biopharmaceutical company’s stock valued at $12,447,000 after purchasing an additional 130,108 shares in the last quarter. Archer Investment Corp purchased a new stake in Halozyme Therapeutics in the second quarter valued at approximately $78,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $9,710,000. Finally, Orion Capital Management LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $337,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 42,478 shares of company stock valued at $3,767,304. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $105.35 on Monday. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.66. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a 50 day simple moving average of $87.01 and a two-hundred day simple moving average of $74.74. The firm has a market cap of $11.96 billion, a P/E ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research reports. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.